Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: Intrauterine device (IUD) expulsion increases the risk of unintended pregnancy; how timing of postpartum IUD insertion and breastfeeding are associated with risk of expulsion is relevant to the benefit-risk profile.

Objective: To evaluate the association of postpartum timing of IUD insertion and breastfeeding status with incidence and risk of IUD expulsion.

Design, Setting, And Participants: The Association of Perforation and Expulsion of Intrauterine Devices (APEX-IUD) cohort study included women aged 50 years or younger with an IUD insertion between 2001 and 2018. The breastfeeding analysis focused on a subcohort of women at 52 or fewer weeks post partum with known breastfeeding status. The study was conducted using data from electronic health records (EHRs) at 4 research sites with access to EHR: 3 Kaiser Permanente sites (Northern California, Southern California, Washington) and the Regenstrief Institute (Indiana). Data analysis was conducted from June to November 2019.

Exposures: Timing of IUD insertion post partum was categorized into discrete time periods: 0 to 3 days, 4 days to 6 or fewer weeks, more than 6 weeks to 14 or fewer weeks, more than 14 weeks to 52 or fewer weeks, and non-post partum (>52 weeks or no evidence of delivery). Breastfeeding status at the time of insertion was determined from clinical records, diagnostic codes, or questionnaires from well-baby visits.

Main Outcomes And Measures: Incidence rates and adjusted hazard ratios (aHRs) were estimated using propensity scores to adjust for confounding.

Results: The full cohort included 326 658 women (mean [SD] age, 32.0 [8.3] years; 38 911 [11.9%] Asian or Pacific Islander; 696 [0.2%] Hispanic Black; 56 180 [17.2%] Hispanic other; 42 501 [13.0%] Hispanic White; 28 323 [8.7%] non-Hispanic Black; 137 102 [42.0%] non-Hispanic White), and the subcohort included 94 817 women. Most IUDs were levonorgestrel-releasing (259 234 [79.4%]). There were 8943 expulsions. The 5-year cumulative incidence of IUD expulsion was highest for insertions 0 to 3 days post partum (10.73%; 95% CI, 9.12%-12.61%) and lowest for insertions more than 6 weeks to 14 or fewer weeks post partum (3.18%; 95% CI, 2.95%-3.42%). Adjusted HRs using women with non-post partum IUD insertion as the referent were 5.34 (95% CI, 4.47-6.39) for those with postpartum insertion at 0 to 3 days; 1.22 (95% CI, 1.05-1.41) for those with postpartum insertion at 4 days to 6 or fewer weeks; 1.06 (95% CI, 0.95-1.18) for those with postpartum insertion at more than 6 to 14 or fewer weeks; and 1.43 (95% CI, 1.29-1.60) for those with postpartum insertion at more than 14 to 52 or fewer weeks. In the subcohort, 5-year cumulative incidence was 3.49% (95% CI, 3.25%-3.73%) for breastfeeding women and 4.57% (95% CI, 4.22%-4.95%) for nonbreastfeeding women; the adjusted HR for breastfeeding vs not breastfeeding was 0.71 (95% CI, 0.64-0.78).

Conclusions And Relevance: In this study of real-world data, IUD expulsion was rare but more common with immediate postpartum insertion. Breastfeeding was associated with lower expulsion risk.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886522PMC
http://dx.doi.org/10.1001/jamanetworkopen.2021.48474DOI Listing

Publication Analysis

Top Keywords

fewer weeks
32
iud insertion
20
postpartum insertion
20
insertion breastfeeding
16
post partum
16
intrauterine device
12
insertion
12
iud expulsion
12
breastfeeding status
12
weeks
12

Similar Publications

Impact of personalized nursing on the quality of life in lung cancer patients.

Front Oncol

August 2025

Health Management Department, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide. As systemic therapy prolongs survival, improving patients' quality of life (QoL) has become a central goal of holistic care. Personalized nursing interventions, tailored to individual patient needs, have shown promise in oncology but lack large-scale evaluation in lung cancer populations.

View Article and Find Full Text PDF

Introduction/aims: Therapeutic electrical stimulation (ES) of repaired nerves has been demonstrated to improve muscle function. Previous studies applied ES to the proximal transected nerve end (P-ES) with benefits to the neuronal cell body. We investigated whether a single ES dose applied to the distal end (D-ES) or distal and proximal ends (DP-ES) prior to nerve repair provides benefits to neuromuscular junction (NMJ) and muscle recovery.

View Article and Find Full Text PDF

[Speech markers as objective indicators of apathy: New insights from a case study].

Encephale

September 2025

Speech and Language Pathology Department of Nice, Faculty of Medicine, Campus Pasteur, université Côte d'Azur, 28, avenue de Valombrose, 06107 Nice, France; Cognition Behaviour Technology Laboratoy (CoBTeK), institut Claude-Pompidou, université Côte d'Azur, 10, rue Molière, 06000 Nice, France.

Introduction: Apathy, commonly observed in neurocognitive disorders, is characterized by a reduction in goal-directed behavior with a reduction of initiatives interests and emotions. This article presents the case of Mrs. B.

View Article and Find Full Text PDF

Sexual assault is a pervasive problem, particularly for US college women. Although many recover naturally, a significant minority develop posttraumatic stress disorder (PTSD) or alcohol misuse. Intervening acutely can prevent chronic psychopathology from developing.

View Article and Find Full Text PDF

Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.

View Article and Find Full Text PDF